Tandem Diabetes (TNDM) Misses Q1 EPS by 23c, Beats on Revenues; Offers FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Tandem Diabetes (TNDM) Misses Q1 EPS by 23c, Beats on Revenues; Offers FY18 Revenue Outlook

Tandem Diabetes Care (TNDM) PT Raised to $7.50 at Stifel

April 27, 2018 10:32 AM EDT

Stifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $7.50 while maintaining a Hold rating.

... More

Tandem Diabetes Care (TNDM) PT Raised to $9 at Cowen; More Upside

April 27, 2018 7:48 AM EDT

Cowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $9.00 (from $7.00) while maintaining a Outperform rating.

Analyst Doug Schenkel commented, "TNDM posted a solid Q1 beat. We expect numerous revenue growth catalysts (new products, renewals, Animas, international, infusion sets) to drive upside to... More